Puma Biotechnology Inc. (PBYI)
Statistics
Share Statistics
Puma Biotechnology has 51.62M shares outstanding. The shares have a market value of 449.61M.
| 51.62M | |
| 2.8% | |
| 0.19% | |
| 76.85% | |
| 39.6M | |
| 5,289 | |
| n/a |
Short Selling Information
Short interest in Puma Biotechnology is 8.07% of the outstanding shares, representing 4.13M shares. The short ratio is 12.16.
| 4.13M | |
| 8.07% | |
| 9.47% | |
| 12.16 |
Valuation Ratios
The stock has a PE ratio of 17.42, meaning that every $1 in earnings is currently priced at $17.42 in the stock market.
| 17.42 | |
| 24.89 | |
| 1.94 | |
| 1.96 | |
| 3.21 | |
| 10.92 | |
| n/a |
Enterprise Valuation
The enterprise value is 360.52M. Enterprise value adds debt and subtracts cash from the company's market cap, providing an alternative valuation for the company.
| 1.56 | |
| 8.99 | |
| 8.76 | |
| 8.76 |
Financial Position
Puma Biotechnology's current ratio is 2.91. A current ratio above 1 means that the company has enough short-term assets to cover its short-term liabilities.
| 2.91 | |
| 2.57 | |
| 0.03 | |
| 0.11 | |
| 0.12 | |
| 9.86 |
Financial Efficiency
Return on Equity is 21.97%, and return on invested capital is 24.2%.
| 21.97% | |
| 9.81% | |
| 24.2% | |
| $1.29M | |
| $149.26K | |
| 179 | |
| 1.2 | |
| 4.37 |
Taxes
| 4.45M | |
| 14.28% |
Stock Price Statistics
The stock price has increased by 52.01% in the past year.
| 1.22 | |
| 52.01% | |
| 7.9 | |
| 6.73 | |
| 65.27 | |
| 310,203 |
Income Statement
In the last 12 months, Puma Biotechnology had revenue of 231.24M and earned 26.72M in profits. Earnings per share was 0.5.
| 231.24M | |
| 173.04M | |
| 30.44M | |
| 26.72M | |
| 45.17M | |
| 34.69M | |
| 0.5 |
Balance Sheet
Puma Biotechnology has 36.54M in cash on the balance sheet. Total assets are 192.74M, and total liabilities are 4.82M.
| 36.54M | |
| 4.82M | |
| 31.72M | |
| -1.28B | |
| 192.74M | |
| 95.25M |
Cash Flow
Puma Biotechnology's operating cash flow was 41.15M over the trailing twelve months.
| 41.15M | |
| 10K | |
| 41.16M | |
| 0.797 |
Margins
Puma Biotechnology's gross profit margin was 74.83%, while its operating and net profit margins were 13.16% and 11.55%, respectively.
| 74.83% | |
| 13.16% | |
| 13.48% | |
| 11.55% | |
| 19.53% | |
| 15% | |
| 17.8% |
Analyst Forecast
According to 1 stock analysts, the average 12-month price target for Puma Biotechnology is $6. The average analyst rating is "Hold".
| $6 | |
| -31.11% | |
| Hold | |
| 1 |
Fair Value
There are several formulas that can be used to estimate the fair value of a stock. The Graham Number estimates a fair value of $5.49, representing a potential upside of -36.97%.
| n/a | |
| n/a | |
| 5.49 | |
| -36.97% |
Scores
| -1.93 | |
| 7 |